Randomized controlled study between balloon and drill dilator as dilation device during EUS-guided hepaticogastrostomy - Randomized controlled study between balloon and drill dilator as dilation device during EUS-guided hepaticogastrostomy

开始日期2022-12-01

申办/合作机构-

100 项与 Atrial natriuretic factor prohormone 31-67(Madeleine Pharmaceuticals) 相关的临床结果

登录后查看更多信息

100 项与 Atrial natriuretic factor prohormone 31-67(Madeleine Pharmaceuticals) 相关的转化医学

登录后查看更多信息

100 项与 Atrial natriuretic factor prohormone 31-67(Madeleine Pharmaceuticals) 相关的专利（医药）

登录后查看更多信息

项与 Atrial natriuretic factor prohormone 31-67(Madeleine Pharmaceuticals) 相关的文献（医药）

2021-12-01·BMC Cancer2区 · 医学

Topical estrogen, testosterone, and vaginal dilator in the prevention of vaginal stenosis after radiotherapy in women with cervical cancer: a randomized clinical trial

2区 · 医学

ArticleOA

作者: Costa-Paiva, Lúcia ; Baccaro, Luiz Francisco ; Vaz, Ana Francisca ; Grion, Regina Celia ; Martins, Jumara

AbstractBackgroundWe aimed to evaluate the effects of different therapeutic options to prevent the evolution of vaginal stenosis after pelvic radiotherapy in women with cervical cancer.Methodsopen-label randomized clinical trial of 195 women, stage I-IIIB, aged 18–75 years, using topical estrogen (66), topical testosterone (34), water-based intimate lubricant gel (66), and vaginal dilators (29) to assess the incidence and severity of vaginal stenosis after radiotherapy at UNICAMP-Brazil, from January/2013 to May/2018. The main outcome measure was vaginal stenosis assessed using the Common Terminology Criteria for Adverse Events (CTCAE) scale and percental changes in vaginal volume. The women were evaluated at four different times: shortly after the end of radiotherapy, and four, eight, and 12 months after the beginning of the intervention. Statistical analysis was carried out using Symmetry test, Kruskal-Wallis test and multiple regression.Resultsthe mean age of women was 46.78 (±13.01) years, 61,03% were premenopausal and 73,84% had stage IIB-IIIB tumors. The mean reduction in vaginal volume in the total group was 25.47%, with similar worsening in the four treatment groups with no statistical difference throughout the intervention period. There was worsening of vaginal stenosis evaluated by CTCAE scale after 1 year in all groups (p < 0.01), except for the users of vaginal dilator (p = 0.37).Conclusionsthere was a reduction in vaginal volume in all treatment groups analyzed, with no significant difference between them. However, women who used vaginal dilators had a lower frequency and severity of vaginal stenosis assessed by the CTCAE scale after one year of treatment.Trial registrationBrazilian Registry of Clinical Trials, RBR-23w5fv. Registered 10 January 2017 - Retrospectively registered.

2020-05-01·Hypertension1区 · 医学

Cardioprotective Effects of the Novel Compound Vastiras in a Preclinical Model of End-Organ Damage

1区 · 医学

Article

作者: Cataliotti, Alessandro ; Altara, Raffaele ; Zouein, Fouad A. ; Frisk, Michael ; Louch, William E. ; da Silva, Gustavo J.J. ; Spelta, Francesco ; Booz, George W.

Cardiac hypertrophy and renal damage associated with hypertension are independent predictors of morbidity and mortality. In a model of hypertensive heart disease and renal damage, we tested the actions of continuous administration of Vastiras, a novel compound derived from the linear fragment of ANP (atrial natriuretic peptide), namely pro-ANP 31–67 , on blood pressure and associated renal and cardiac function and remodeling. Of note, this peptide, unlike the ring structured forms, does not bind to the classic natriuretic peptide receptors. Dahl/Salt–Sensitive rats fed a 4% NaCl diet for 6 weeks developed hypertension, cardiac hypertrophy, and renal damage. Four weeks of treatment with 50 to 100 ng/kg per day of Vastiras exhibited positive effects on renal function, independent of blood pressure regulation. Treated rats had increased urine excretion, natriuresis, and enhanced glomerular filtration rate. Importantly, these favorable renal effects were accompanied by improved cardiac structure and function, including attenuated cardiac hypertrophy, as indicated by decreased heart weight to body weight ratio, relative wall thickness, and left atrial diameter, as well as reduced fibrosis and normalized ratio of the diastolic mitral inflow E wave to A wave. A renal subtherapeutic dose of Vastiras (25 ng/kg per day) induced similar protective effects on the heart. At the cellular level, cardiomyocyte size and t-tubule density were preserved in Vastiras-treated compared with untreated animals. In conclusion, these data demonstrate the cardiorenal protective actions of chronic supplementation of a first-in-class compound, Vastiras, in a preclinical model of maladaptive cardiac hypertrophy and renal damage induced by hypertension.

2018-06-01·Clinical Oral Investigations2区 · 医学

The effectiveness of two types of MADS for OSA therapy

2区 · 医学

Article

作者: Bollen, Klara Hilda Alphonsine ; Kramer, Gerbrand Johannes Cornelis ; Verburg, Francis Emma ; Donker, Henk-Jan

OBJECTIVESThe purpose of this study was to determine differences in effectiveness between two types of mandibular advancement device (MAD).MATERIAL AND METHODSIn this retrospective, cohort study, the two devices used were MAD type "Somnodent-Flex" (MAD 1) and MAD type "Herbst" (MAD 2). One hundred thirty-seven patients participated in this study, 67 patients were treated with MAD 1, and 70 patients with MAD 2. The indication MAD with obstructive sleep apnea (OSA) is based on a polysomnography test, in accordance with the CBO guidelines. The effectiveness of MAD therapy can be determined by a second polysomnography test (with the MAD in situ). The apnea-hypopnea index (AHI) is registered during the first and the second polysomnography test. Changes in these values determine the effectiveness.RESULTSA significant decrease in AHI was found regarding T1 and T2 for both the MADs: F (1, 134) = 140,850, p < 0,001. The mean differences of both the MADs turned out to correlate to T1. After correcting for this covariance, there was no significant difference between the two MAD devices regarding the AHI value: F (1, 134) = 1160, p = 0,283.CONCLUSIONSThe results of the present study show no significant difference in effectiveness between MAD 1 and MAD 2 in respect to the AHI value.CLINICAL RELEVANCESince 2012, healthcare insurance companies in the Netherlands refunds MAD type "Somnodent" used for treatment of sleep apnea. It is important to investigate if this type of MAD is as more effective or less effective as other types of MADs. If research points out that other MADs are more effective in reducing the sleep apnea, refund policies have to be adapted.

100 项与 Atrial natriuretic factor prohormone 31-67(Madeleine Pharmaceuticals) 相关的药物交易

登录后查看更多信息